Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Gouni-Berthold

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Current Pharmaceutical Design|March 23, 2011
Cardiovascular disease: focus on dyslipidemiaI Gouni-Berthold
Current Pharmaceutical Design|April 14, 2004
Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseasesI Gouni-Berthold, A Sachinidis
Current Drug Targets. Cardiovascular & Haematological Disorders|March 1, 2006
Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosisI Gouni-Berthold, W Krone
Deutsche Medizinische Wochenschrift (1946)|December 2, 2006
[Favorable effects of decreasing lipids in patients with diabetes mellitus]I Gouni-Berthold, W Krone
Zeitschrift Fur Kardiologie|November 1, 2005
Hypertriglyceridemia-why, when and how should it be treated?I Gouni-Berthold, W Krone
Current Pharmaceutical Design|March 23, 2011
Antisense oligonucleotides for the treatment of dyslipidemiaI Gouni-Berthold, H K Berthold
Handbook of Experimental Pharmacology|October 3, 2012
Role of physician gender in drug therapyI Gouni-Berthold, H K Berthold
Current Pharmaceutical Design|November 15, 2011
Role of physician gender in the quality of care of cardiometabolic diseasesI Gouni-Berthold, H K Berthold
Current Medicinal Chemistry|October 2, 2015
Treatment of Cardiovascular Risk Factors in WomenI Gouni-Berthold, H K Berthold
Innere Medizin (Heidelberg, Germany)|June 6, 2023
[Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations]G Klose, I Gouni-Berthold, W März
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Current Pharmaceutical Design|March 23, 2011
Cardiovascular disease: focus on dyslipidemiaI Gouni-Berthold
Current Pharmaceutical Design|April 14, 2004
Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseasesI Gouni-Berthold, A Sachinidis
Current Drug Targets. Cardiovascular & Haematological Disorders|March 1, 2006
Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosisI Gouni-Berthold, W Krone
Deutsche Medizinische Wochenschrift (1946)|December 2, 2006
[Favorable effects of decreasing lipids in patients with diabetes mellitus]I Gouni-Berthold, W Krone
Zeitschrift Fur Kardiologie|November 1, 2005
Hypertriglyceridemia-why, when and how should it be treated?I Gouni-Berthold, W Krone
Current Pharmaceutical Design|March 23, 2011
Antisense oligonucleotides for the treatment of dyslipidemiaI Gouni-Berthold, H K Berthold
Handbook of Experimental Pharmacology|October 3, 2012
Role of physician gender in drug therapyI Gouni-Berthold, H K Berthold
Current Pharmaceutical Design|November 15, 2011
Role of physician gender in the quality of care of cardiometabolic diseasesI Gouni-Berthold, H K Berthold
Current Medicinal Chemistry|October 2, 2015
Treatment of Cardiovascular Risk Factors in WomenI Gouni-Berthold, H K Berthold
Innere Medizin (Heidelberg, Germany)|June 6, 2023
[Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations]G Klose, I Gouni-Berthold, W März
Pageof 5